TY - JOUR
T1 - Oral Tacrolimus Bioavailability Is Increased After Right Split Liver Transplantation
AU - Wilberg, J.
AU - Küpper, B.
AU - Thrum, K.
AU - Bärthel, E.
AU - Koch, A.
AU - Settmacher, U.
AU - Kornberg, A.
PY - 2007/12
Y1 - 2007/12
N2 - Objective: Tacrolimus (Tac) is mainly metabolized in the liver. The aim of this trial was to analyze Tac bioavailability after partial liver transplantation. Patients and Methods: A total of 33 patients after right split liver grafting (n = 8 living related, LRLT; n = 8 cadaver split, CS) or full-size liver transplantation (n = 17, FS) were included in this trial. All of them received Tac perorally with an initial dose of 2 × 5 mg/d. Dose adjustment was performed according to the Tac trough level (T0) with an initial target T0 levels of 12 to 15 ng/mL. Results: The time to reach target T0 levels tended to be lower (P = .05) in the split liver groups (LRLT: 2.8 ± 1.6 days; CS: 2.1 ± 0.9 days; FS: 4.5 ± 3.2 days). In addition, mean Tac dose to maintain the target T0 level was significantly decreased (P = .01) in the split liver cohorts (LRLT: 5.8 ± 1.1 mg/d; CS: 5.5 ± 2.5 mg/d; FS: 9.8 ± 3.9 mg/d). Only graft weight/standard liver volume ratio (r = .566, P = .02) and graft weight/body weight ratio (r = .709, P = .002) showed significant correlations with Tac maintenance doses in the split liver group. Conclusions: Peroral Tac bioavailability was significantly higher after partial liver transplantation using the right hepatic lobe compared with full-size transplants. The volume of the split liver graft highly correlated with Tac maintenance therapy and should be used to calculate the most appropriate initial posttransplantation Tac dose.
AB - Objective: Tacrolimus (Tac) is mainly metabolized in the liver. The aim of this trial was to analyze Tac bioavailability after partial liver transplantation. Patients and Methods: A total of 33 patients after right split liver grafting (n = 8 living related, LRLT; n = 8 cadaver split, CS) or full-size liver transplantation (n = 17, FS) were included in this trial. All of them received Tac perorally with an initial dose of 2 × 5 mg/d. Dose adjustment was performed according to the Tac trough level (T0) with an initial target T0 levels of 12 to 15 ng/mL. Results: The time to reach target T0 levels tended to be lower (P = .05) in the split liver groups (LRLT: 2.8 ± 1.6 days; CS: 2.1 ± 0.9 days; FS: 4.5 ± 3.2 days). In addition, mean Tac dose to maintain the target T0 level was significantly decreased (P = .01) in the split liver cohorts (LRLT: 5.8 ± 1.1 mg/d; CS: 5.5 ± 2.5 mg/d; FS: 9.8 ± 3.9 mg/d). Only graft weight/standard liver volume ratio (r = .566, P = .02) and graft weight/body weight ratio (r = .709, P = .002) showed significant correlations with Tac maintenance doses in the split liver group. Conclusions: Peroral Tac bioavailability was significantly higher after partial liver transplantation using the right hepatic lobe compared with full-size transplants. The volume of the split liver graft highly correlated with Tac maintenance therapy and should be used to calculate the most appropriate initial posttransplantation Tac dose.
UR - http://www.scopus.com/inward/record.url?scp=37049026889&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2007.03.102
DO - 10.1016/j.transproceed.2007.03.102
M3 - Article
C2 - 18089362
AN - SCOPUS:37049026889
SN - 0041-1345
VL - 39
SP - 3237
EP - 3238
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 10
ER -